|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate:a case report显示文摘Gastrointestinal stromal tumors (GISTs) are rare tumors, which represent approximately 1% of the neoplasms of the gastrointestinal tract. These tumors rarely give extra-abdominal metastases. However, their clinical outcome is potentially adverse. In some rare cases, co- existance of GISTs with other malignancies has been reported. Here we present a case of a 74-year old male with GIST, which was managed by surgical resection. Fourteen months later, the patient presented with liver metastases and imatinib mesylated was administered. During treatment, the patient reported skeletal pain and plane X-rays revealed osteolytic bone lesions. Further investigation revealed the presence of multiple myeloma. To the best of our knowledge, this is the first report of the co-existence of multiple myeloma (MM) with GIST. | D Tzilves A Gatopoulou A Tarpagos I Katsos K Zervas E Katodritou F Patakiouta | 2007 | World Journal of Gastroenterology2007，13，13： | 2 |
| 2 | Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents显示文摘 | Terpos E Anargyrou K Katodritou E | 2012 | Int J Cancer2012，130，3： | 1 |
| 3 | Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration显示文摘 | Terpos E Katodritou E Tsiftsakis E | | 0，，03： | 1 |
| 4 | High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents 显示文摘 | Terpos E Katodritou E Roussou M | 2010 | Eur J Haematol2010，85，2： | 1 |
| 5 | VAD-doxil versus VAD-doxil plus thal- idomide as initial treatment for multiple myeloma: results ofa multicenter randomi- ,zed trial of the Greek Myeloma Study Group 显示文摘 | Zervas K Mihou D Katodritou E | 2007 | Ann Oncol2007，18，8： | 1 |
| 6 | Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response 显示文摘 | Katodritou E Ganz T Terpos E | 2009 | Am J Hematol2009，84，8： | 1 |
| 7 | Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration显示文摘 | Terpos E Katodritou E Tsiftsakis E | 2009 | Haematologica2009，94，3： | 1 |
| 8 | Successful treatment of extramedullary gastric plasmacytoma with the combination of bort- ezomib and dexamethasone: first reported case显示文摘 | Katodritou E Kartsios C Gastari V | 2008 | Leuk Res2008，32，2： | 1 |
| 9 | Response of primary plasma cell leukemia to the com- bination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics in- fluence treatment outcome显示文摘 | KATODRITOU E VERROU E GASTARI V | 2008 | ? Leuk Res2008，32，： | 1 |
| 10 | Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration 显示文摘 | Terpos E Katodritou E Tsiftsakis E | 2009 | Haematologica2009，94，： | 1 |
| 11 | Elevated cir- culating sclerostin correlates with advanced disease fea- tures and abnormal bone remodeling in symptomatic mye- loma: reduction post-bortezomib monotherapy显示文摘 | Terpos E Christoulas D Katodritou E | 2012 | Int J Cancer2012，131，6： | 1 |
| 12 | Erythropoiesis?stimulating agents are associated with reduced survival in patients with multiple myeloma 显示文摘 | Katodritou E Verrou E Hadjiaggelidou C | 2008 | Am J Hematol2008，83，9： | 1 |
| 13 | Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents显示文摘 | Dimopoulos MA Delimpasi S Katodritou E | 2014 | Ann Oncol2014，25，1： | 1 |
| 14 | Cystatin-C is an independ- ent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration显示文摘 | Terpos E Katodritou E Tsiftsakis E | 2009 | Haematologica2009，94，3： | 1 |
| 15 | Cystatin-C is an independ- ent prognostic factor for survival in multiple myeloma and is reducedby bortezomib administration 显示文摘 | Terpos E Katodritou E Tsiftsakis E | 2009 | Haematologica2009，94，3： | 1 |
| 16 | Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? 显示文摘 | KATODRITOU E GASTARI V VERROU E | 2009 | Leuk Res2009，33，8： | 1 |
| 17 | Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics influence treatment outcome显示文摘 | Katodritou E Verrou E GastariV | | 0，，07： | 1 |
| 18 | Is it possible to cure myeloma without allogeneic transplantation?显示文摘 | Katodritou E Papadaki S Konstantinidou P | 2016 | Transfus Apher Sci2016，54，： | 1 |
| 19 | Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders显示文摘 | Speletas M Katodritou E Daiou C | 2007 | Leuk Res2007，31，： | 1 |
| 20 | Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? 显示文摘 | Katodritou E Verrou E Gastari V | 2008 | Leuk Res2008，32，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员